Jerad Dalton
Psychiatry · Indianapolis, INNPI 1306835418
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,611 of the $20,049 with a category attached, or 67.9%. 32 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 40.4% of the total. Reporting peaked in 2023 at $8,006 and has fallen 75.0% since, to $2,002 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,015 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$8K
- AbbVie$2K
- Johnson & Johnson$2K
- Bausch Health US, LLC$807
- Ironshore Pharmaceuticals Inc.$682
- Otsuka America Pharmaceutical, Inc.$613
- plus $5K from 26 others
What the payments were for
- Speaking & faculty fees$4,62523%
- Travel & lodging$1,7549%
- Food & beverage$13,61168%
- Education$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 194 | $8,101 |
| AbbVie(2 entities) | 154 | $2,491 |
| Johnson & Johnson | 153 | $2,249 |
| Bausch Health US, LLC | 99 | $807 |
| Ironshore Pharmaceuticals Inc. | 53 | $682 |
| Otsuka America Pharmaceutical, Inc. | 36 | $613 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $552 |
| Neos Therapeutics, LP | 35 | $544 |
| Corium, LLC | 36 | $496 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $480 |
| Axsome Therapeutics, Inc. | 18 | $332 |
| Vanda Pharmaceuticals Inc. | 11 | $299 |
| Lundbeck LLC | 19 | $279 |
| Adlon Therapeutics L.p. | 28 | $279 |
| Tris Pharma Inc | 16 | $238 |
| Merck | 14 | $192 |
| Neuronetics, Inc. | 5 | $190 |
| Eisai Inc. | 12 | $181 |
| Noven Therapeutics, LLC | 10 | $178 |
| Neurocrine Biosciences, Inc. | 8 | $164 |
| Collegium Pharmaceutical, Inc. | 16 | $160 |
| Alkermes, Inc. | 9 | $138 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| OWP Pharmaceuticals, Inc. | 3 | $60 |
| Vertical Pharmaceuticals, LLC | 3 | $45 |
| Rhodes Pharmaceuticals L.p. | 2 | $42 |
| Brainsway USA Inc | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Alfasigma USA, Inc. | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,049 in reported general payments places this provider in the 95th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 13 | $20,672 |
| AdderallDextroamphetamine/Amphetamine | 12 | $11,761 |
| TrintellixVortioxetine Hydrobromide | 11 | $10,836 |
| Ziprasidone Hcl | 12 | $4,533 |
| Clozapine | 28 | $1,820 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $1,056 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $863 |
| Bupropion XlBupropion Hcl | 19 | $744 |
| Trazodone Hcl | 16 | $659 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $564 |
| Olanzapine | 14 | $551 |
| Paroxetine Hcl | 13 | $387 |
| Buspirone Hcl | 12 | $264 |
| Sertraline Hcl | 29 | $255 |
| AmantadineAmantadine Hcl | 13 | $214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Adderall, Trintellix | $480 | $22,59723 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $552 | $20,67213 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $25529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Charles BeasleyIndianapolis$129K
- Dmitry ArbuckIndianapolis$40K
- Albert AllenIndianapolis$24K
- Alan BreierIndianapolis$19K
- Kristen DaussIndianapolis$16K
- Anantha ShekharIndianapolis$13K
- Maria ValenaIndianapolis$11K
- Robert BakerIndianapolis$11K
- Areef KassamIndianapolis$10K
- Judi KnowlesIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.